Skip to main content
ELVNEnliven Therapeutics, Inc.Sell5.5·$46.53
ELVN · Why this verdict

Why Enliven Therapeutics (ELVN) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Enliven Therapeutics is a pre-revenue biotech with 30.8% upside to the analyst target and strong momentum, but quality is far below the floor, it burns cash, and its pipeline depends on one drug.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The pipeline depends on ELVN-001 and a single supplier, Pharmaron, so one failure would hit the company hard.

↑Improving
Bear case
Expectation
A second program advances to the clinic over 12 months.

CounterThe lead drug may be strong enough to carry the company alone.

Upside of 30.8% to the $64.67 analyst target against 15.0% downside gives a reward-to-risk ratio of 2.06.

→Stable
Estimated upside
Expectation
Price closes part of the gap to the $64.67 target over 12 months.

CounterBiotech targets depend on trial outcomes and can be cut sharply on one data release.

Quality scores 1.6, below the 4.0 floor, with negative free cash flow and no competitive moat.

→Stable
Quality breakdown
Expectation
Quality rises above 3.0 as spending is funded without dilution.

CounterA pre-revenue biotech is expected to burn cash, so a low quality score says little about pipeline value.

Momentum scores 6.7 with RSI of 79 and rising on-balance volume, while 18% of shares are sold short.

Tripped↓Deteriorating
Momentum breakdown
Expectation
Price holds above the 200-day average and RSI falls back below 70.

CounterAn RSI near 80 with 89% implied volatility makes a sharp pullback likely.

Insiders sold $2.23M across 13 sales over 90 days, though institutions are accumulating.

→Stable
Insider breakdown
Expectation
Insider selling falls below $500K over 90 days.

CounterSales are only 0.061% of market cap and may be routine.

Per-dimension breakdown

Value

9.0/10data confidence 33%
ComponentSub-score
Analyst target9.0
  • ▸Attractively valued

Quality

1.6/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio5.0
FCF quality0.0
Moat4.8
Piotroski F4.4
  • ▸Cash-burning (FCF negative)
  • ▸No competitive moat
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

4.8/10data confidence 100%
ComponentSub-score
RSI5.5
MACD0.9
OBV10.0
MA position6.0
Volume1.5
  • ▸Volume accumulation (rising OBV)
  • ▸Above 200-day MA

Sentiment

7.8/10data confidence 100%
ComponentSub-score
Analyst rating8.4
Price target9.7
erm sentiment4.7
  • ▸Analyst upside: 60%

Insider

5.4/10data confidence 100%
ComponentSub-score
materiality4.5
insider conviction2.0
holder change8.2
notable moves7.0
  • ▸Modest insider selling — $1,585,364 (0.046% of mkt cap)
  • ▸Institutions accumulating

Peer rank

6.5/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank6.6
growth rank5.0
  • ▸Conservative debt levels

Technical

5.0/10data confidence 100%
ComponentSub-score
bollinger5.1
support resistance5.0
52w position4.9

Risk (lower is worse)

5.5/10data confidence 100%
ComponentSub-score
short interest1.5
days to cover3.6
volatility0.0
put call10.0
implied vol3.5
beta10.0
debt equity10.0
  • ▸High short interest justified: 20%
  • ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

3.8/10data confidence 100%
ComponentSub-score
erm5.0
earnings history3.3
earnings timing5.0
surprise avg1.7
  • ▸Earnings concerns: 2B/2M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (8)
  • MOMENTUM:4.8>=4.5
  • ASYMMETRY:3.2>=1.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:102d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)

none

Warning (1)
  • MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
3.22
Upside
+39.0%
Downside
12.1%
Sizing output
AVOID

SetupRange Bound — RSI 54 mid-range, Bollinger mid-band

EdgeNo clear edge — No clear edge identified

SuitabilitySpeculative — Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 3.22.

The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Peer rank at 6.5; the weakest are Quality at 1.6, Catalyst at 3.8, and Momentum at 4.8. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.22 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Analyst Upside To Target

    Trip ifUpside to the analyst target falls below 10% from the current 30.8%.

  • P2Cash Burning Low Quality

    Trip ifQuality score rises above 3.0 from the current 1.6.

  • P3Single Asset Pipeline Concentration

    Trip ifA second program enters clinical trials, taking pipeline programs in the clinic to at least 2.

  • P4Overbought Momentum High Short InterestTripped

    Trip ifRSI falls below 60 from the current 79 while price stays above the 200-day average.

  • P5Insider Selling

    Trip ifNet insider selling exceeds $10M over 90 days.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › ELVN › Why this verdict